Pediatric haematopoiesis and related malignancies

Jin, Man-Wen; Xu, Sihua; An, Q.

doi:10.3892/ol.2017.6106

Cited by 1 publication

(2 citation statements)

References 39 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 One group of BM malignancies originates in myeloid cell lineages, called myeloid malignancies. 1,2 These comprise myelodysplastic syndromes (MDSs), myeloproliferative neoplasms (MPNs), MDS/MPN overlapping syndromes, and acute myeloid leukemia (AML). Table 1 presents the different characteristics of these myeloid malignancies, illustrating their overlapping and distinguishing parameters.…”

Section: Introductionmentioning

confidence: 99%

“…For example, MPNs are characterized by the accumulation of a malignant cell clone as a result of somatic mutations that lead to its aberrantly upregulated proliferative capacity. 2 This hyperproliferation results from specific driver mutations, such as JAK2-V617F and BCR-ABL mutations, that encode cell signaling proteins, which deregulate pathways of cell proliferation. [3][4][5][6][7][8] This ultimately leads to hypercellularity of mature blood cells in the BM and peripheral blood.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The potential of proliferative and apoptotic parameters in clinical flow cytometry of myeloid malignancies

et al. 2021

View full text Add to dashboard Cite

Standardization of the detection and quantification of leukocyte differentiation markers by the EuroFlow Consortium has led to a major step forward in the integration of flow cytometry into classification of leukemia and lymphoma. In our opinion, this now enables introduction of markers for more dynamic parameters, such as proliferative and (anti)apoptotic markers, which have proven their value in the field of histopathology in the diagnostic process of solid tumors and lymphoma. Although use of proliferative and (anti)apoptotic markers as objective parameters in the diagnostic process of myeloid malignancies was studied in the past decades, this did not result in the incorporation of these biomarkers into clinical diagnosis. This review addresses the potential of these markers for implementation in the current, state-of-the-art multiparameter analysis of myeloid malignancies. The reviewed studies clearly recognize the importance of proliferation and apoptotic mechanisms in the pathogenesis of bone marrow (BM) malignancies. The literature is, however, contradictory on the role of these processes in myelodysplastic syndrome (MDS), MDS/myeloproliferative neoplasms, and acute myeloid leukemia. Furthermore, several studies underline the need for the analysis of the proliferative and apoptotic rates in subsets of hematopoietic BM cell lineages and argue that these results can have diagnostic and prognostic value in patients with myeloid malignancies. Recent developments in multiparameter flow cytometry now allow quantification of proliferative and (anti)apoptotic indicators in myeloid cells during their different maturation stages of separate hematopoietic cell lineages. This will lead to a better understanding of the biology and pathogenesis of these malignancies.

show abstract

Section: Introductionmentioning

confidence: 99%